Cargando…
A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
BACKGROUND: Indoleamine 2, 3-dioxygenase is an enzyme that causes immunosuppression in tumors. Indoximod inhibits the indoleamine 2, 3-dioxygenase pathway and enhances immunologic responses to dendritic cell (DC) vaccines preclinically. Adenovirus p53 (Ad.p53) is used to generate DC vaccines against...
Autores principales: | Soliman, Hatem, Khambati, Fatema, Han, Hyo S., Ismail-Khan, Roohi, Bui, Marilyn M., Sullivan, Daniel M., Antonia, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839376/ https://www.ncbi.nlm.nih.gov/pubmed/29515795 http://dx.doi.org/10.18632/oncotarget.24118 |
Ejemplares similares
-
A phase I study of indoximod in patients with advanced malignancies
por: Soliman, Hatem H., et al.
Publicado: (2016) -
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
por: Soliman, Hatem H., et al.
Publicado: (2014) -
Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer
por: Fox, Eric, et al.
Publicado: (2018) -
First Report of Parkinsonism Associated With Indoximod, an
Immune-Modulating Agent
por: Floyd, Mark, et al.
Publicado: (2016) -
A dual-responsive doxorubicin–indoximod conjugate for programmed chemoimmunotherapy
por: Yang, Zhaoxuan, et al.
Publicado: (2022)